Lakefront Biotherapeutics (LKFT) Non Operating Income (2016 - 2024)

Lakefront Biotherapeutics (LKFT) has reported Non Operating Income for 7 consecutive years, with $4.8 million the latest figure, recorded in Q4 2024.

• Quarterly Non Operating Income changed N/A year-over-year to $4.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$65.5 million (changed N/A YoY) and the FY2024 annual result came in at $4.8 million, up 740.0% from the prior year.
• Non Operating Income climbed to $4.8 million in Q4 2024 per LKFT's latest filing, from -$154.0 million in the prior quarter.
• Over the last five years, Non Operating Income for LKFT reached as high as $68.0 million in Q3 2022 and fell as low as -$154.0 million in Q4 2022.
• A 3-year average of -$16.4 million and a median of $10.2 million in 2024 frame the typical range for Non Operating Income.
• The largest YoY upside for Non Operating Income was 336.5% in 2022 against a maximum downside of 336.5% in 2022.
• Year by year, Non Operating Income stood at $15.6 million in 2021, then sank by 1087.59% to -$154.0 million in 2022, then surged by 103.1% to $4.8 million in 2024.
• According to Business Quant data, Non Operating Income over the past three periods registered $4.8 million, -$154.0 million, and $68.0 million for Q4 2024, Q4 2022, and Q3 2022 respectively.